Company intelligence / Profile preview

ONCOdianova

Hamburg, Hamburg, Germany

Ownership: Private
Development stage: Other

Overview

ONCOdianova is a German biotechnology company focused on the development of innovative oncology therapeutics and companion diagnostics. The company specializes in the identification and validation of novel biomarkers to guide personalized cancer treatment, particularly in the field of targeted therapies and immunotherapy. ONCOdianova leverages its expertise in antibody development and molecular pathology to create tools that improve patient stratification and treatment monitoring. Their research efforts are primarily directed toward addressing resistance mechanisms in solid tumors, such as colorectal and lung cancers.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyAntibodySmall molecule
Industry: Biotech

Partnerships

dianova GmbHUniversity Medical Center Hamburg-Eppendorf (UKE)

Beyond the preview

Go deeper on ONCOdianova.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ONCOdianova.

Explore the full profile